Delphinus Medical Technologies Raises $30M in Series D Funding

Delphinus Medical Technologies, Inc., a Novi, MI-based medical imaging company, raised $30M in Series D funding.

Backers included Arboretum Ventures, Beringea, North Coast Technology Investors, Venture Investors, Hopen Life Science Ventures, and Waycross Ventures.

The company intends to use the funds to commercialize its SoftVue™ 3D Whole Breast Ultrasound Tomography System worldwide.

Led by CEO Mark J. Forchette, Delphinus Medical Technologies designs and manufactures a 3D whole breast ultrasound system that utilizes a dynamic new technique to image the breast with the use of sound and water. SoftVue™ is a 3D whole breast ultrasound tomography system that delivers no radiation, requires no compression, and images the entire breast with a single scan. It has previously received three 510(k)s, and the PMA approval for dense breast screening adjunct to mammography expands the company’s existing platform of approvals to include breast cancer screening in asymptomatic women with dense breast parenchyma after confirmation that the breast density composition is BI-RADS c or d at the time of screening mammography. The device is not intended to be used as a replacement for screening mammography. SoftVue can be used at the same visit as screening mammography, and the SoftVue images are intended to be interpreted with the mammogram results to enhance screening.

Delphinus was founded as a spin out of the Karmanos Cancer Institute in Detroit.

FinSMEs

30/09/2022